Patents by Inventor Ju Du
Ju Du has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11928271Abstract: A method is provided. The method comprises: obtaining, by a processing system and using a set of rotation electrodes that interact with the knob interface, first resulting signals and second resulting signals; determining, by the processing system, an initial state of the knob interface using the first resulting signals and the second resulting signals; obtaining, by the processing system and using the set of rotation electrodes, third resulting signals indicating a first rotational state of the knob interface, based at least in part on the knob interface being rotated from the initial state to the first rotational state; determining, by the processing system, the rotational direction of the knob interface using the first resulting signals, the second resulting signals, and the third resulting signals; and adjusting, by the processing system, a setting using the determined rotational direction.Type: GrantFiled: August 24, 2022Date of Patent: March 12, 2024Assignee: Synaptics IncorporatedInventors: Kelvin Fong, Tomohiro Hirakawa, Yan-Ju Du
-
Publication number: 20240069655Abstract: A method is provided. The method comprises: obtaining, by a processing system and using a set of rotation electrodes that interact with the knob interface, first resulting signals and second resulting signals; determining, by the processing system, an initial state of the knob interface using the first resulting signals and the second resulting signals; obtaining, by the processing system and using the set of rotation electrodes, third resulting signals indicating a first rotational state of the knob interface, based at least in part on the knob interface being rotated from the initial state to the first rotational state; determining, by the processing system, the rotational direction of the knob interface using the first resulting signals, the second resulting signals, and the third resulting signals; and adjusting, by the processing system, a setting using the determined rotational direction.Type: ApplicationFiled: August 24, 2022Publication date: February 29, 2024Inventors: Kelvin Fong, Tomohiro Hirakawa, Yan-Ju Du
-
Publication number: 20240050373Abstract: The present disclosure provides a dry powder composition of treprostinil prodrugs and a method of treating pulmonary hypertension (e.g., pulmonary arterial hypertension), portopulmonary hypertension, or pulmonary fibrosis in a patient in need thereof. The dry powder composition includes (a) from about 0.1 wt % to about 3 wt % of a compound of Formula (I): or an enantiomer, diastereomer, or a pharmaceutically acceptable salt thereof, (b) from about 0.01 wt % to about 3 wt % of DSPE-PEG2000, (c) from about 10 wt % to about 50 wt % of leucine, and the balance being (d) a sugar selected from the group consisting of trehalose and mannitol. The entirety of (a), (b), (c), and (d) is 100 wt %, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl. The method includes administering an effective amount of the dry powder composition to the lungs of the patient by inhalation via a dry powder inhaler. In certain compositions and methods provided herein, R1 is hexadecyl, e.g., linear hexadecyl.Type: ApplicationFiled: July 27, 2023Publication date: February 15, 2024Applicant: Insmed IncorporatedInventors: Ju DU, Adam PLAUNT, Vladimir MALININ
-
Patent number: 11759425Abstract: The present disclosure provides a dry powder composition of treprostinil prodrugs and a method of treating pulmonary hypertension (e.g., pulmonary arterial hypertension), portopulmonary hypertension, or pulmonary fibrosis in a patient in need thereof. The dry powder composition includes (a) from about 0.1 wt % to about 3 wt % of a compound of Formula (I): or an enantiomer, diastereomer, or a pharmaceutically acceptable salt thereof, (b) from about 0.01 wt % to about 3 wt % of DSPE-PEG2000, (c) from about 10 wt % to about 50 wt % of leucine, and the balance being (d) a sugar selected from the group consisting of trehalose and mannitol. The entirety of (a), (b), (c), and (d) is 100 wt %, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl. The method includes administering an effective amount of the dry powder composition to the lungs of the patient by inhalation via a dry powder inhaler. In certain compositions and methods provided herein, R1 is hexadecyl, e.g., linear hexadecyl.Type: GrantFiled: August 23, 2022Date of Patent: September 19, 2023Assignee: Insmed IncorporatedInventors: Ju Du, Adam Plaunt, Vladimir Malinin
-
Publication number: 20220409537Abstract: The present disclosure provides a dry powder composition of treprostinil prodrugs and a method of treating pulmonary hypertension (e.g., pulmonary arterial hypertension), portopulmonary hypertension, or pulmonary fibrosis in a patient in need thereof. The dry powder composition includes (a) from about 0.1 wt % to about 3 wt % of a compound of Formula (I): or an enantiomer, diastereomer, or a pharmaceutically acceptable salt thereof, (b) from about 0.01 wt % to about 3 wt % of DSPE-PEG2000, (c) from about 10 wt % to about 50 wt % of leucine, and the balance being (d) a sugar selected from the group consisting of trehalose and mannitol. The entirety of (a), (b), (c), and (d) is 100 wt %, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl. The method includes administering an effective amount of the dry powder composition to the lungs of the patient by inhalation via a dry powder inhaler. In certain compositions and methods provided herein, R1 is hexadecyl, e.g., linear hexadecyl.Type: ApplicationFiled: August 23, 2022Publication date: December 29, 2022Applicant: Insmed IncorporatedInventors: Ju DU, Adam PLAUNT, Vladimir MALININ
-
Patent number: 11458098Abstract: The present disclosure provides a dry powder composition of treprostinil prodrugs and a method of treating pulmonary hypertension (e.g., pulmonary arterial hypertension), portopulmonary hypertension, or pulmonary fibrosis in a patient in need thereof. The dry powder composition includes (a) from about 0.1 wt % to about 3 wt % of a compound of Formula (I): or an enantiomer, diastereomer, or a pharmaceutically acceptable salt thereof, (b) from about 0.01 wt % to about 3 wt % of DSPE-PEG2000, (c) from about 10 wt % to about 50 wt % of leucine, and the balance being (d) a sugar selected from the group consisting of trehalose and mannitol. The entirety of (a), (b), (c), and (d) is 100 wt %, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl. The method includes administering an effective amount of the dry powder composition to the lungs of the patient by inhalation via a dry powder inhaler. In certain compositions and methods provided herein, R1 is hexadecyl, e.g., linear hexadecyl.Type: GrantFiled: April 28, 2020Date of Patent: October 4, 2022Assignee: Insmed IncorporatedInventors: Ju Du, Adam Plaunt, Vladimir Malinin
-
Patent number: 10967065Abstract: In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms.Type: GrantFiled: April 30, 2019Date of Patent: April 6, 2021Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Hugh Smyth, Ju Du
-
Publication number: 20200338005Abstract: The present disclosure provides a dry powder composition of treprostinil prodrugs and a method of treating pulmonary hypertension (e.g., pulmonary arterial hypertension), portopulmonary hypertension, or pulmonary fibrosis in a patient in need thereof. The dry powder composition includes (a) from about 0.1 wt % to about 3 wt % of a compound of Formula (I): or an enantiomer, diastereomer, or a pharmaceutically acceptable salt thereof, (b) from about 0.01 wt % to about 3 wt % of DSPE-PEG2000, (c) from about 10 wt % to about 50 wt % of leucine, and the balance being (d) a sugar selected from the group consisting of trehalose and mannitol. The entirety of (a), (b), (c), and (d) is 100 wt %, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl. The method includes administering an effective amount of the dry powder composition to the lungs of the patient by inhalation via a dry powder inhaler. In certain compositions and methods provided herein, R1 is hexadecyl, e.g., linear hexadecyl.Type: ApplicationFiled: April 28, 2020Publication date: October 29, 2020Inventors: Ju DU, Adam PLAUNT, Vladimir MALININ
-
Publication number: 20200093931Abstract: In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms.Type: ApplicationFiled: April 30, 2019Publication date: March 26, 2020Inventors: Hugh SMYTH, Ju Du
-
Patent number: 10272158Abstract: In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms. The present invention provides, in various aspects, compounds and methods for the treatment of infections, such as biofilm infections or chronic biofilm infections. The chronic biofilm infection may occur in wounds, implanted devices, immunocompromised patients, people with cystic fibrosis, eye infections, etc.Type: GrantFiled: July 2, 2015Date of Patent: April 30, 2019Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Hugh Smyth, Ju Du
-
Publication number: 20170143842Abstract: In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms. The present invention provides, in various aspects, compounds and methods for the treatment of infections, such as biofilm infections or chronic biofilm infections. The chronic biofilm infection may occur in wounds, implanted devices, immunocompromised patients, people with cystic fibrosis, eye infections, etc.Type: ApplicationFiled: July 2, 2015Publication date: May 25, 2017Inventors: Hugh SMYTH, Ju Du